Viraben R, Aquilina C
Service de Dermatologie, Toulouse, France.
AIDS. 1998 Apr 16;12(6):F37-9. doi: 10.1097/00002030-199806000-00001.
Lipodystrophies are rare cutaneous disorders characterized by the symmetrical loss of subcutaneous fat from the body surface. The cause of lipodystrophy is not known, but a possible genetic predisposition is likely and either overt diabetes mellitus or insulin resistance are often associated.
Case study.
Eight patients who developed either partial or generalized lipodystrophy after protease inhibitor therapy.
In all eight patients lipodystrophy occurred after 2-12 months of starting indinavir and was not preceded by weight loss or inflammatory skin disease. Short-term follow-up after withdrawal of therapy showed no change in the patients' appearance. One patient developed glycosuria as lipodystrophy became manifest. In three cases glucose tolerance test was performed revealing a high level of insulin between the first and third hour of loading.
In our view, lipodystrophy is an unwanted side-effect of protease inhibitor therapy causing noticeable disfigurement.
脂肪营养不良是一种罕见的皮肤疾病，其特征为体表皮下脂肪的对称性缺失。脂肪营养不良的病因尚不清楚，但可能存在遗传易感性，且常伴有显性糖尿病或胰岛素抵抗。
病例研究。
8例在接受蛋白酶抑制剂治疗后出现部分或全身性脂肪营养不良的患者。
所有8例患者在开始使用茚地那韦2 - 12个月后出现脂肪营养不良，且在出现之前无体重减轻或炎症性皮肤病。停药后的短期随访显示患者外观无变化。1例患者在脂肪营养不良出现时出现糖尿。3例患者进行了葡萄糖耐量试验，结果显示在负荷后第一小时至第三小时之间胰岛素水平较高。
我们认为，脂肪营养不良是蛋白酶抑制剂治疗的一种不良副作用，会导致明显的容貌毁损。
